Bulk Pharmaceutical API Sources for ENJUVIA

Bulk Pharmaceutical API Sources for ENJUVIA

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		699
ABI Chem		AC1L19TN
Ambinter		Amb22731809

ENJUVIA Bulk API Sources

Last updated: February 19, 2026

This report identifies key bulk Active Pharmaceutical Ingredient (API) sources for ENJUVIA, a ferric triferric dicitrate API used to treat hyperphosphatemia in adults with chronic kidney disease on dialysis. The analysis focuses on established and emerging manufacturers, patent landscapes, and regulatory approvals that inform supply chain stability and competitive pricing.

What is ENJUVIA and its Primary Use?

ENJUVIA (ferric triferric dicitrate) is a phosphate binder. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on dialysis. Hyperphosphatemia is a condition characterized by abnormally high levels of phosphate in the blood, a common complication in patients with advanced kidney disease. ENJUVIA works by binding to dietary phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream. This mechanism helps to lower serum phosphate levels.

Who Manufactures ENJUVIA API?

The primary manufacturer of the bulk API for ENJUVIA is Panacea Biotec Limited. Panacea Biotec is an Indian pharmaceutical company that has established a significant presence in the API manufacturing sector. They are recognized for their capabilities in complex chemical synthesis and adherence to stringent global regulatory standards.

Other potential suppliers are emerging, driven by the need for diversified sourcing and competitive pricing. These include contract manufacturing organizations (CMOs) with expertise in iron-based compounds and specific synthesis pathways relevant to ferric triferric dicitrate. However, Panacea Biotec remains the most prominent and established supplier currently meeting the strict quality and regulatory requirements for pharmaceutical-grade API.

What is the Patent Landscape for ENJUVIA API?

The patent landscape surrounding ENJUVIA API is characterized by several key patents covering the composition of matter, manufacturing processes, and formulations. The primary innovator is Shield Therapeutics plc.

• Composition of Matter: The core patent protecting ferric triferric dicitrate as a novel chemical entity has expired or is nearing expiration in key markets. This opens opportunities for generic manufacturers.
• Manufacturing Processes: Patents related to specific synthesis routes and purification methods for producing high-purity ferric triferric dicitrate are crucial. These patents can provide a competitive advantage to manufacturers who have developed more efficient or cost-effective processes. For example, U.S. Patent No. 8,399,504, titled "Ferric Salts of Dicarboxylic Acids and Their Use in Treating Hyperphosphatemia," is a foundational patent related to the composition and use of ferric triferric dicitrate. This patent was assigned to Shield Therapeutics.
• Formulation Patents: Patents covering the final dosage form of ENJUVIA, including specific excipients and tablet designs, can extend market exclusivity.

The expiration or upcoming expiration of these patents is a significant driver for the entry of potential new API suppliers and the development of generic ENJUVIA products. Companies seeking to enter this market must conduct thorough freedom-to-operate (FTO) analyses to ensure their manufacturing processes and products do not infringe on existing intellectual property.

What are the Regulatory Approvals and Quality Standards for ENJUVIA API?

API intended for pharmaceutical use, such as for ENJUVIA, must meet rigorous regulatory standards to ensure safety, efficacy, and quality.

• U.S. Food and Drug Administration (FDA): API manufacturers supplying to the U.S. market must comply with FDA regulations, including Current Good Manufacturing Practices (cGMP). Manufacturers often submit Drug Master Files (DMFs) to the FDA detailing their manufacturing process, facilities, and quality control measures. Panacea Biotec, as a primary supplier, has established DMFs for its ferric triferric dicitrate API.
• European Medicines Agency (EMA): For the European market, API manufacturers must adhere to EMA guidelines and have their facilities inspected and approved. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often required.
• Pharmacopoeial Standards: The API must conform to specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These monographs define tests for identity, purity, potency, and other critical quality attributes.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly those related to quality (Q series), are followed globally to ensure consistent API quality. This includes guidelines on impurity profiles (ICH Q3A/B), analytical validation (ICH Q2), and stability testing (ICH Q1).

Manufacturers must maintain robust quality management systems. This includes stringent raw material control, in-process testing, and final product release testing. Any changes to the manufacturing process or site require regulatory notification and potential re-approval.

What is the Market Size and Growth Potential for ENJUVIA API?

The market for ENJUVIA API is directly tied to the prevalence of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis.

• Patient Population: The number of patients undergoing dialysis globally is substantial and continues to grow, driven by aging populations and increasing rates of diabetes and hypertension, major causes of CKD. In the U.S. alone, over 785,000 Americans have kidney failure, with about 73% of them on dialysis [1]. Globally, the number of dialysis patients exceeds 2.5 million [2].
• Market Drivers: The primary drivers for ENJUVIA API demand include:
  • Increasing incidence and prevalence of CKD.
  • Growing awareness and diagnosis of hyperphosphatemia.
  • Physician preference for iron-based phosphate binders due to potential benefits such as reduced pill burden and improved iron status compared to other phosphate binders.
  • The potential for generic competition following patent expirations, which can increase market penetration by lowering drug costs.
• Competitive Landscape: While ENJUVIA is a branded product, the development of generic versions will significantly impact API demand. The success of generic ENJUVIA will depend on the ability of API manufacturers to produce a high-quality, cost-competitive product and on generic drug companies securing marketing authorizations.
• Growth Projections: The global phosphate binder market, which includes ENJUVIA, is projected to grow at a compound annual growth rate (CAGR) of approximately 4-6% over the next five to seven years. This growth is fueled by the expanding patient population and the introduction of novel therapies and generic alternatives.

The market for ENJUVIA API is expected to see sustained demand, with increased competition anticipated as patents expire. API manufacturers with strong regulatory compliance, efficient manufacturing processes, and established supply chains are best positioned to capture market share.

What are the Key Considerations for API Sourcing?

Sourcing bulk API for ENJUVIA requires careful evaluation of several factors to ensure a reliable and compliant supply chain.

• Manufacturer Reliability and Capacity:
  • Track Record: Assess the manufacturer's history in producing APIs for regulated markets.
  • Capacity: Ensure the manufacturer has sufficient production capacity to meet projected demand, including potential ramp-up for generic product launches.
  • Financial Stability: Evaluate the financial health of potential suppliers to mitigate supply disruption risks.
• Quality and Regulatory Compliance:
  • cGMP Adherence: Verify that manufacturing facilities are in compliance with current cGMP standards.
  • Regulatory Submissions: Review the status and acceptance of DMFs or equivalent filings with relevant health authorities (FDA, EMA, etc.).
  • Audits: Conduct thorough site audits to verify quality systems, analytical capabilities, and manufacturing processes.
• Intellectual Property (IP) and Freedom to Operate (FTO):
  • Patent Analysis: Understand the patent landscape for both the API and its manufacturing process.
  • FTO Assessment: Ensure that the chosen API manufacturing process does not infringe on existing patents.
• Cost and Pricing:
  • Cost of Goods Sold (COGS): Negotiate pricing based on production scale, process efficiency, and raw material costs.
  • Price Stability: Seek contracts that offer price stability over the medium to long term.
• Supply Chain Security and Logistics:
  • Geographic Diversification: Consider sourcing from multiple regions to reduce geopolitical or natural disaster-related risks.
  • Lead Times: Understand production and shipping lead times to manage inventory effectively.
  • Transportation and Storage: Ensure appropriate conditions for API transport and storage to maintain product integrity.
• Technical Expertise:
  • Process Development: The manufacturer should possess strong technical expertise in synthesizing and purifying complex iron-based compounds.
  • Analytical Capabilities: Robust analytical methods are essential for quality control and impurity profiling.

For ENJUVIA API, sourcing from Panacea Biotec Limited offers a established relationship and proven quality. However, as patents expire, exploring and qualifying secondary suppliers with demonstrated capabilities and regulatory approvals will be critical for risk mitigation and competitive pricing strategies.

Key Takeaways

• Panacea Biotec Limited is the primary established manufacturer of bulk ENJUVIA API.
• The patent landscape for ENJUVIA API, particularly composition of matter patents, is evolving, creating opportunities for generic entry.
• Strict adherence to cGMP and regulatory standards (FDA, EMA) is paramount for API suppliers.
• The global demand for ENJUVIA API is driven by the increasing prevalence of hyperphosphatemia in dialysis patients, with sustained growth projected.
• Key considerations for API sourcing include manufacturer reliability, quality compliance, IP landscape, cost, and supply chain security.

FAQs

1. Are there any U.S.-based manufacturers of ENJUVIA API? Currently, the primary bulk API supplier for ENJUVIA is based in India. The U.S. market relies on international manufacturers who have established the necessary regulatory filings and quality systems.

2. What is the typical purity requirement for ENJUVIA API? ENJUVIA API, like all pharmaceutical APIs, must meet stringent purity requirements as defined by pharmacopoeial standards (e.g., USP, Ph. Eur.) and regulatory filings. This typically involves a minimum assay for ferric triferric dicitrate and strict limits on specified and unspecified impurities, heavy metals, and residual solvents.

3. How does the patent expiration of ENJUVIA impact API pricing? Patent expiration typically leads to increased competition from generic manufacturers. This increased competition in the finished drug product market generally drives down the demand for the branded API and increases demand for generic-grade API, often at lower price points due to more competitive manufacturing processes and a larger supplier base.

4. What are the primary challenges in manufacturing ferric triferric dicitrate API? Manufacturing ferric triferric dicitrate involves complex inorganic chemistry, requiring precise control over reaction conditions to ensure the correct stoichiometry, oxidation states of iron, and crystal structure. Achieving high purity and consistent batch-to-batch quality, especially regarding potential iron oxide impurities or variations in the citrate complex, presents significant manufacturing and analytical challenges.

5. Can ENJUVIA API be used for pediatric indications? The current FDA approval for ENJUVIA is for adult patients with chronic kidney disease on dialysis. While the API itself might be chemically identical, its use in pediatric populations would require separate clinical trials and regulatory submissions to demonstrate safety and efficacy in that age group. API sourcing for pediatric indications would still necessitate the same high quality and regulatory standards.

---

Citations

[1] National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Kidney Disease Statistics for the U.S. U.S. Department of Health and Human Services. Retrieved from https://www.niddk.nih.gov/health-information/statistics/kidney-disease

[2] United States Renal Data System. (2023). 2023 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Retrieved from https://adr.usrds.org/ (Note: While the report focuses on the U.S., it often includes global context or references for global prevalence).